MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2018 International Congress

    Effects of JN403, an α-7-nicotine-acetylcholine-receptor (α7-nAChR) agonist on human alpha-synuclein-mediated in vitro and in vivo models of Parkinson’s disease

    B. Lee, C. Noelker, W. Chiu, D. Feuerbach, L. Timmerman, W. Oertel (Marburg, Germany)

    Objective: To investigate whether JN403, a novel selective agonist of α-7-nicotine-acetylcholine-receptors (α7-nAChRs) can suppress inflammation and toxicity in human alpha-synuclein (αSyn) induced in vitro and…
  • 2018 International Congress

    Identification and analysis of differential miRNA in exosomes of dopaminergic neurons overexpressing α-synuclein

    Y. Liang, D. Lin, T. Zhou, D. Zheng (Guangzhou, China)

    Objective: The aim of this study was to compare the miRNA expression in secreted exosomes from dopaminergic neurons overexpressing α-synuclein with healthy neurons. Background: Exosomes,…
  • 2018 International Congress

    Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)

    L. Chahine, T. Beach, C. Coffey, C. Caspell-Garcia, C. Alder, G. Serrano, S. Mosovsky, T. Foroud, C. Linder, H. Riss, D. Ecklund, J. Seibyl, A. Mallya, V. Arnedo, L. Riley, K. Dave, D. Jennings, B. Mollenhauer (Pittsburgh, PA, USA)

    Objective: To characterize the distribution of alpha-synuclein (aSyn) pathology in multiple tissues and body fluids within the same Parkinson’s disease (PD) subjects and compared to…
  • 2018 International Congress

    Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy

    P. Howson, T. Johnston, J. Brotchie, M. Hill, J. Koprich (Toronto, ON, Canada)

    Objective: We evaluated the efficacy of JNX3001 in an aSyn-based macaque model with plasma exposures associated with efficacy in rodents. Background: Alpha-synuclein (aSyn) deposition is…
  • 2018 International Congress

    Investigating the influence of alpha-synuclein promoter (Rep1) polymorphism on cognition, disability and plasma alpha-synuclein levels in Parkinson’s disease

    YJ. Tan, Y. Zhao, ZH. Lu, S. Ng, E. Ng, F. Setiawan, WL. Au, EK. Tan, L. Tan, A. Ng (Singapore, Singapore)

    Objective: We sought to investigate the relationship between SNCA Rep1 allele length and cognitive, motor and disability scores in PD, as well with plasma alpha-synuclein…
  • 2018 International Congress

    Insulin degrading enzyme, a novel key protein against alpha-synuclein oligomers formation?

    I. Martinez-Valbuena, R. Valenti-Azcarate, I. Amat-Villegas, I. Marcilla-Garcia, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, MT. Tuñon-Alvarez, MR. Luquin-Piudo (Pamplona, Spain)

    Objective: The objective of this work is to study the interaction between α-synuclein and the insulin degrading enzyme in the pancreas of subjects with synucleinopathies.…
  • 2018 International Congress

    Elevated serum α-synuclein levels in Huntington’s disease patients

    M. Breza, E. Emmanouilidou, G. Karadima, C.H. Kartanou, M. Panas, K. Vekrellis, G. Koutsis (Athens, Greece)

    Objective: To investigate serum α-synuclein levels in Huntington’s disease (HD) patients. Background: HD is a heredodegenerative disease caused by mutations in HTT coding for huntingtin…
  • 2018 International Congress

    Levels of plasma alpha-synuclein as measured using Single Molecule Array technology is higher in Parkinson’s disease compared to controls and is not influenced by LRRK2 genotype

    YJ. Tan, A. Ng, ZH. Lu, S. Ng, E. Ng, F. Setiawan, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

    Objective: To investigate plasma alpha-synuclein levels in PD using ultra-sensitive protein detection technology, and to determine the association of plasma alpha-synuclein with cognitive, motor and…
  • 2018 International Congress

    Salivary Alpha-Synuclein a new tool for the diagnosis of Parkinson’s disease?

    C. Aerts, C. Hirtz, V. Gonzalez, L. Collombier, M. De Verdal, C. Geny, M. Charif, E. Moulis, P. Fabbro-Peray, D. Deville Periere, P. Lapeyrie, G. Castelnovo, S. Lehmann (Nimes, France)

    Objective: The aim of the PARKSYN study was to test the utility of salivary alpha-synuclein (a-syn) concentration in the differential diagnosis between Parkinson's disease (PD)…
  • 2018 International Congress

    Pronounced synucleinopathy and nigrostriatal degeneration result in forelimb use deficits in the rat preformed alpha-synuclein fibril model

    J. Patterson, M. Duffy, T. Collier, K. Luk, C. Kemp, J. Howe, P. Patel, A. Stoll, K. Miller, N. Kanaan, K. Paumier, C. Sortwell (Grand Rapids, MI, USA)

    Objective: Generation of a synucleinopathy model in rats using injections of α-synuclein preformed fibrils (α-syn PFFs) resulting in robust and widespread α-syn pathology and at…
  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 51
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley